

Thaw and Culture Details

Cell Line Name	PENN029i-752-3							
WiCell Lot Number	DB36392							
Provider	University of Pennsylvania – Dr. Daniel Rader							
Banked By	Penn Institute for Regenerative Medicine iPS Core Facility							
Thaw and Culture Recommendations	WiCell recommends thawing 1 vial into 1 wells of a 6 well plate. WiCell recommends thawing using ROCK Inhibitor for best results.							
Culture Platform	Feeder Dependent							
	Medium: hESC Medium (KOSR)							
Matrix: MEF								
Protocol	WiCell Feeder Dependent Protocol							
Passage Number	p12 These cells were cultured for 12 passages prior to freeze and post colony picking. Therefore, plated cells at thaw should be labeled passage 13.							
Date Vialed	19-May-2015							
Vial Label	iPS-752 Sev3 P12 05-19-15 JS							
Biosafety and Use Information	Appropriate biosafety precautions should be followed when working with these cells. The end user is responsible for ensuring that the cells are handled and stored in an appropriate manner. WiCell is not responsible for damages or injuries that may result from the use of these cells. Cells distributed by WiCell are intended for research purposes only and are not intended for use in humans.							

Testing Performed by WiCell

Test Description	Test Provider	Test Method	Test Specification	Result					
	WiCell	SOP-CH-003	Expected karyotype	Pass					
	Results: 46,XY Nonclonal finding: 46,XY,t(4;8)(q34;q12)								
Karyotype by G-banding	Interpretation: This is a normal karyotype. No clonal abnormalities were detected at the stated								
		band level of resolution. There is one nonclonal finding, listed above. Nonclonal findings likely result							
	from technical artifact, but	from technical artifact, but may be due to a developing clonal abnormality or to low-level mosaicism.							
Post-Thaw Viable Cell Recovery			≥ 15 Undifferentiated Colonies,						
	WiCell	SOP-CH-305	≤ 30% Differentiation and	Pass					
		501-011-505	recoverable attachment after	1 435					
			passage						
	UW Translational	PowerPlex 16 HS							
Identity by STR	Research Initiatives in	System by	Defines profile	Pass					
	Pathology Laboratory	Promega							
Sterility	Steris	ST/07	Negative	Pass					
Mycoplasma	WiCell	SOP-QU-004	Negative	Pass					

©2016 WiCell Research Institute

The material provided under this certificate has been subjected to the tests specified and the results and data described herein are accurate based on WiCell's reasonable knowledge and belief. Appropriate Biosafety Level practices and universal precautions should always be used with this material. For clarity, the foregoing is governed solely by WiCell's Terms and Conditions of Service, which can be found at http://www.wicell.org/privacyandterms.



Testing Reported by Provider

The Provider stated that some or all of the additional analyses listed below may have been performed for this cell line. For more information, publication and dbGaP links, where available, are provided on the cell line specific web page on the WiCell website.

- SNP microarray
- Flow Cytometry (Tra1-60 and SSEA-4)Differentiation into hepatocytes
- Infinium[®] Expanded Multi-Ethnic Genotyping Array (MEGA^{EX})

Approval Date	Quality Assurance Approval			
23-June-2016	4/21/2018 XG Quality Assurance Signed by: Gay, Jenna			


©2016 WiCell Research Institute



Date Reported: Monday, March 19, 2018 Cell Line: PENN029i-752-3-DB36392 13499 Passage#: 14 Date of Sample: 3/13/2018 Specimen: Human IPS Results: 46,XY Cell Line Gender: Male Reason for Testing: lot release testing

Investigator: WiCell

Nonclonal finding: 46,XY,t(4;8)(q34;q12)



Cell: 19 Slide: G02 Slide Type: Karyotype Total Counted: 20 Total Analyzed: 8 Total Karyogrammed: 4

Band Resolution: 400 - 500

Interpretation:

This is a normal karyotype. No clonal abnormalities were detected at the stated band level of resolution.

There is one nonclonal finding, listed above. Nonclonal findings likely result from technical artifact, but may be due to a developing clonal abnormality or to low-level mosaicism.



Limitations: This assay allows for microscopic visualization of numerical and structural chromosome abnormalities. The size of structural abnormality that can be detected is >3-10Mb, dependent upon the G-band resolution obtained from this specimen. For the purposes of this report, band level is defined as the number of G-bands per haploid genome. It is documented here as "band level", i.e., the range of bands determined from the four karyograms in this assay. Detection of heterogeneity of clonal cell populations in this specimen (i.e., mosaicism) is limited by the number of metaphase cells examined, documented here as "# of cells counted".

This assay was conducted solely for listed investigator/institution. The results may not be relied upon by any other party without the prior written consent of the Director of the WiCell Cytogenetics Laboratory. The results of this assay are for research use only. If the results of this assay are to be used for any other purpose, contact the Director of the WiCell Cytogenetics Laboratory.

Unless otherwise mutually agreed in writing, the services provided to you hereunder by WiCell Research Institute, Inc. ("WiCell") are governed solely by WiCell's Terms and Conditions of Service, found at www.wicell.org/privacyandterms. Any terms you may attach to a purchase order or other document that are inconsistent, add to, or conflict with WiCell's Terms and Conditions of Service are null and void and of no legal force or effect.



HISTOLOGY - IHC - MOLECULAR - IMAGING

Department of Pathology and Laboratory Medicine TRIP Laboratory (Molecular) http://www.pathology.wisc.edu/research/trip

Sample Report: 13302-STR Sample Name on Tube: 13302-STR 56.3 ng/μL, (A260/280=2.77) Sample Type: Cells Cell Count: ~2 million cells **Requestor:** WiCell Research Institute Quality Department info@wicell.org (888) 204-1782

WiCell®

Sample Date: N/A Receive Date: 02/12/18 Assay Date: 02/13/18 File Name: STR 180214 wmr Report Date: 02/16/18

STR Locus	STR Genotype Repeat #	STR Genotype
FGA	16–18,18.2,19,19.2,20,20.2,21,21.2,22, 22.2, 23, 23.2, 24, 24.2, 25, 25.2, 26–30, 31.2, 43.2, 44.2,45.2, 46.2	Identifying information has
TPOX	6-13	been redacted to
D8S1179	7-18	protect donor
vWA	10-22	confidentiality. If
Amelogenin	X,Y	more information
Penta D	2.2, 3.2, 5, 7-17	is required,
CSF1PO	6-15	please, contact
D16S539	5, 8-15	- <u>WiCell's Technical</u> - Support.
D7S820	6-14	<u>Support.</u>
D13S317	7-15	
D5S818	7-16	
Penta E	5-24	
D18S51	8-10, 10.2, 11-13, 13.2, 14-27	
D21S11	24,24.2,25,25.2,26-28,28.2,29,29.2, 30, 30.2,31, 31.2,32,32.2,33,33.2, 34,34.2,35,35.2,36-38	
TH01	4-9,9.3,10-11,13.3	
D3S1358	12-20	

<u>Results:</u> Based on the 13302-STR cells submitted by WiCell QA dated and received on 02/12/18, this sample (Label on Tube: 13302-STR) defines the STR profile of the human stem cell line PENN029i-752-3 comprising 26 allelic polymorphisms across the 15 STR loci analyzed.

<u>Interpretation:</u> No STR polymorphisms other than those corresponding to the human PENN029i-752-3 stem cell line were detected and the concentration of DNA required to achieve an acceptable STR genotype (signal/ noise) was equivalent to that required for the standard procedure (~1 ng/amplification reaction) from human genomic DNA. This result suggests that the 13302-STR sample submitted corresponds to the PENN029i-752-3 stem cell line and was not contaminated with any other human stem cells or a significant amount of mouse feeder layer cells.

<u>Sensitivity</u>: Sensitivity limits for detection of STR polymorphisms unique to either this or other human stem cell lines is ~2-5%.

X RMB Digitally Signed on 02/16/18	X WMR Digitally Signed on 02/16/18
BA TRIP Laboratory Molecular	, PhD, Director / Co-Director

Testing was accomplished by analysis of human genetic polymorphisms at STR loci. This methodology has not yet been approved by the FDA and is for investigational use only. Acknowledge TRIP in your publications, posters & presentations. For details, see: http://www.pathology.wisc.edu/research/trip/acknowledging TRIP agrees to maintain the confidentiality of any information provided to it in connection with its performance of this STR analysis on the same conditions as set forth in paragraph 2 of WiCell's Terms and Conditions of Service (http://www.wicell.org/media.acux/1a429b84-2b54-44a4-8ad8-5c05db93dd8a).

Short Tandem Repeat

Analysis

Native Product Sterility Report



		SAMPLE #: 18020291						
WiCell		DATE RECEIVED: 06-Fel						
504 S. Rosa Rd., Rm 101	L	TEST INITIATED: 07-Feb						
Madison, WI 53719		TEST COMPLETED: 21-Feb						
Madison, W133719 TEST COMIFLETED: 21- SAMPLE NAME / DESCRIPTION: CREM015i-SS16-1 WB66723 13311, CREM016i-SS18-1 WB66712 13312, CREM019i-SS25-1 WB66723 13313, CREM021i-SS29-1 WB66729 13314, H SOX2-GFP WB66727 13315, WC005i-FX11-7 WB20338 13316, WC009i-FXi WB17924 13317, PENN015i-668-5 DB36410 13318, PENN029i-752-3 DB3 13319, PENN009i-57-52 DB35131 13320, PENN034i-322-1 DB34729 1332 PENN077i-521-1 DB36597 13322, PENN125i-233-4 DB35073 13323, PEN 262-1 DB35081 13324, UCSD048i-52-1 WB66722 13325, UCSD208i-111-1 WB66730 13326, UCSD133i-79-1 WB61228 13327, UCSD152i-11-3 WB612 13328, UCSD168i-22-1 WB61577 13329, UCSD170i-22-3 WB60774 13330, UCSD175i-18-3 WB60837 13331, UCSD066i-67-1 WB60392 13332, UCSD0 35-2 WB65030 13334, UCSD125i-7-2 WB59219 13337, UCSD128i-7-5 WB60297 13338, UCSD151i-11-2 WB59218 13339, UCSD158i-12-4 WB60020 13340, UCSD088i-6-5 WB5942 13341, UCSD147i-10-2 WB54174 13342, UCSD1 18-1 WB54407 13343, UCSD198i-23-1 WB54174 13344, UCSD098i-35-1 WB5 13345, UCSD100i-36-1 WB55460 13346, UCSD129i-75-1 WB54795 13347, UCSD136i-82-1 WB54902 13348, UCSD139i-85-1 WB55345 13349, UCSD1 18-1 WB54899 13350, UCSD187i-104-1 WB55339 13351, UCSD206i-31-1 WB54794 13352, UCSD217i-115-1 WB55069 13353, UCSD208i-116-1 WB5 13354, UCSD097i-34-2 WB57100 13357, UCSD136i-12-2 WB5780 13356, UCSD097i-34-2 WB57100 13357, UCSD136i-1358, UCSD1 70-1 WB55081 13359, UCSD184i-8-1 WB55388 13360, UCSD188i-105-1 WB55081 13359, UCSD184i-8-1 WB55388 13360, UCSD188i-105-1								
PRODUCT REGISTR	ATION:	Other: Human iPS o	cells					
TEST RESULTS:	# Tested	# Positives (Growth) - Control						
TEOTOURNARDY	50	0	3 Negative					
TEST SUMMARY:	# Samples	Media Type	Volume (mL)	Incubation Temperature (° C)	Incubation Duration (Days)			
	50	TSB	40	20-25	14			
	50	FTG	40	30-35	14			
REFERENCE:		Processed according to LAB-003: Sterility Test Procedure						
METHOD VALIDATION / PD #:		000053						
TEST METHODOLOG	34.	USP - Direct Transfer						
	~	Jon Dirottrial						

Native Product Sterility Report



COMMENTS: Sample # 18020291

REVIEWED BY 50

DATE 22 FEBIS

Specific test results may not be indicative of the characteristics of any other samples from the same lot or similar lots. This test report shall not be reproduced, except in full, without prior written approval. Liability is limited to the costs of the tests.



Mycoplasma Detection Assay Report Testing Performed by WiCell

Testing Performed by WiCell Lot Release Testing February 1, 2018 FORM SOP-QU-004.01 Version G Edition 02 Reported by: AP Reviewed by: JB BD Monolight 180

		Reading A A		Α	Read	ling B	В	Ratio		
#	Sample Name	RLU1	RLU2	Ave	RLU1	RLU2	Ave	B/A	Result	Comments/Suggestions
1	PENN029i-752-3-DB36392 13302	399	394	396.5	134	130	132	0.33	Negative	
2	Positive (+) Control	428	443	435.5	14287	14372	14330	32.90	Positive	
3	Negative (-) Control	650	672	661	61	56	58.5	0.09	Negative	

